Psychedelics and the future of medicine
The FDA is offering an 'ultra-fast review' of two psychedelic drugs for treating serious mental health disorders, following a White House executive order to speed up psychedelics research. The FDA's move is a significant development in the potential use of psychedelics in medicine.
The FDA is expediting the review of two psychedelic drugs aimed at treating serious mental health disorders. This decision follows a White House executive order directing the FDA to accelerate research on psychedelics, which are currently illegal under federal law. Dr. Gail Saltz discusses the latest developments surrounding psychedelics. The potential therapeutic use of psychedelics is being explored, with the FDA's 'ultra-fast review' being a key step in this process. The move is part of a broader effort to advance research on psychedelics and their potential medical applications.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.